IceCure Medical Reports Over 30% Q1 U.S. ProSense® Revenue Growth; Cost-Saving Study Wins Award
ICCM sits 29% above its 52-week low of $0.277.
Summary
IceCure Medical announced preliminary Q1 2026 U.S. revenue for its ProSense® system increased over 30% year-over-year, supported by an award-winning study highlighting significant cost savings compared to traditional surgery.
Key Events · Earnings and Guidance · ICCM
-
Strong U.S. Revenue Growth
IceCure Medical expects to report preliminary, unaudited U.S. revenue for ProSense® systems and cryoprobes increased by over 30% in Q1 2026 compared to Q1 2025.
-
Post-FDA Clearance Momentum
The revenue growth is attributed to the adoption of ProSense® following its FDA clearance for low-risk breast cancer in women aged 70 and above in October 2025.
-
Award-Winning Cost-Effectiveness Study
A study featuring ProSense® cryoablation won an SBI 2026 Abstract Award, demonstrating a potential 50%+ reduction in total treatment costs compared to breast-conserving surgery.
-
Expanding Market Presence
The company is expanding its installed base of ProSense® systems in the U.S., including placements at leading academic hospitals, and expects new system sales in Q2 2026.
Analysis · ICCM · Industrial Applications And Services
IceCure Medical reported preliminary, unaudited U.S. revenue growth of over 30% for its ProSense® systems and cryoprobes in the first quarter of 2026 compared to the prior year. This significant operational improvement follows the FDA clearance of ProSense® for low-risk breast cancer in October 2025 and indicates accelerating commercial momentum. The positive news is further bolstered by an award-winning study demonstrating ProSense® cryoablation can reduce treatment costs by more than 50% compared to breast-conserving surgery. This strong performance and clinical validation are particularly important for IceCure Medical, which recently filed an F-3/A shelf registration to address a 'going concern' warning, suggesting these positive developments could help alleviate financial pressures and improve investor sentiment.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICCM was trading at $0.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $24.9M. The 52-week trading range was $0.28 to $1.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.